Dr Sulaiman Al Habib Medical Services (4013) Q3 2025 earnings summary

Executive summary

• Achieved strong revenue growth of 16.35% year-over-year in Q3 2025 and 23.96% for the nine-month period, driven by expansion and operational excellence.

• Report covers financial results for the three and nine months ended 30 September 2025, prepared in accordance with IAS 34 as endorsed in Saudi Arabia.

• The group operates hospitals, pharmacies, and healthcare-related services in Saudi Arabia and the UAE.

• Maintained leadership in medical excellence, technology, and ESG initiatives, earning multiple industry awards and accreditations.

• Continued robust expansion with several new hospitals opened in 2024 and 2025, and multiple future projects underway across Saudi Arabia.

Financial highlights

• Q3 2025 revenue reached 3,463 million, up 16.35% year-over-year; nine-month revenue at 10,005 million, up 23.96%.

• Q3 2025 net income was 602 million, up 1.13% year-over-year; nine-month net income at 1,750 million, up 2.87%.

• Gross profit margin for Q3 2025 was 30.32% (down from 33.33%); EBITDA margin at 25.69% (down from 25.96%).

• Basic and diluted EPS for nine months was 5.00, compared to 4.86 year-over-year.

• Total assets as of 30 September 2025 were 22,788 million, up from 20,558 million at year-end 2024.

Outlook and guidance

• Expansion strategy continues with new hospitals and medical centers under construction and planned openings through 2028.

• Focus on operational efficiency, technology adoption, and service diversification to drive future growth.

• No material impact from new accounting standards effective 2025; no early adoption of standards not yet effective.

• Management expects continued growth in core healthcare and pharmacy segments.